194608-88-3Relevant articles and documents
THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS
-
Page/Page column 28, (2010/11/28)
The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
Novel indole-based peroxisome proliferator-activated receptor agonists: Design, SAR, structural biology, and biological activities
Mahindroo, Neeraj,Huang, Chien-Fu,Peng, Yi-Huei,Wang, Chiung-Chiu,Liao, Chun-Chen,Lien, Tzu-Wen,Chittimalla, Santhosh Kumar,Huang, Wei-Jan,Chai, Chia-Hua,Prakash, Ekambaranellore,Chen, Ching-Ping,Hsu, Tsu-An,Peng, Cheng-Hung,Lu, I-Lin,Lee, Ling-Hui,Chang, Yi-Wei,Chen, Wei-Cheng,Chou, Yu-Chen,Chen, Chiung-Tong,Goparaju, Chandra M. V.,Chen, Yuan-Shou,Lan, Shih-Jung,Yu, Ming-Chen,Chen, Xin,Chao, Yu-Sheng,Wu, Su-Ying,Hsieh, Hsing-Pang
, p. 8194 - 8208 (2007/10/03)
The synthesis and structure-activity relationship studies of novel indole derivatives as peroxisome proliferator-activated receptor (PPAR) agonists are reported. Indole, a druglike scaffold, was studied as a core skeleton for the acidic head part of PPAR
Therapeutic compounds for treating dyslipidemic conditions
-
Page/Page column 12-13, (2010/02/11)
The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.